Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,925 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R, Connors JM; National Cancer Institute of Canada Clinical Trials Group. Kouroukis CT, et al. Among authors: turner r. J Clin Oncol. 2003 May 1;21(9):1740-5. doi: 10.1200/JCO.2003.09.057. J Clin Oncol. 2003. PMID: 12735303 Clinical Trial.
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
Kouroukis CT, Fernandez LA, Crump M, Gascoyne RD, Chua NS, Buckstein R, Turner R, Assouline S, Klasa RJ, Walsh W, Powers J, Eisenhauer E. Kouroukis CT, et al. Among authors: turner r. Leuk Lymphoma. 2011 Mar;52(3):394-9. doi: 10.3109/10428194.2010.546015. Leuk Lymphoma. 2011. PMID: 21323520 Clinical Trial.
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J, Buckstein R, Kassis J, Minden M, Matthews J, Robinson S, Turner R, McIntosh L, Eisenhauer E, Seymour L. Crump M, et al. Among authors: turner r. Leuk Lymphoma. 2010 Feb;51(2):252-60. doi: 10.3109/10428190903585286. Leuk Lymphoma. 2010. PMID: 20109071 Clinical Trial.
The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
Saini L, Brandwein J, Turner R, Larratt L, Hamilton M, Peters A, Wu C, Zhu N, Patterson JM, Bolster L, Mant M, Ritchie B, Liew E, Ghosh S, Sandhu I. Saini L, et al. Among authors: turner r. Eur J Haematol. 2016 Nov;97(5):471-478. doi: 10.1111/ejh.12757. Epub 2016 May 3. Eur J Haematol. 2016. PMID: 27028202
The Adelaide Score: prospective implementation of an artificial intelligence system to improve hospital and cost efficiency.
Kovoor JG, Stretton B, Gupta AK, Beath A, Jacob MO, Kefalianos JM, Carmichael GJ, Zaka A, O'Callaghan G, Satheakeerthy S, Booth A, Delloso T, Hugh TJ, Chan WO, Maddern GJ, Balan-Vnuk E, Cusack M, Gilbert T, Maddison J, Bacchi S; Adelaide Score Advisory Group. Kovoor JG, et al. ANZ J Surg. 2025 Jan 3. doi: 10.1111/ans.19383. Online ahead of print. ANZ J Surg. 2025. PMID: 39754371
Robust, fully-automated assessment of cerebral perivascular spaces and white matter lesions: a multicentre MRI longitudinal study of their evolution and association with risk of dementia and accelerated brain atrophy.
Barisano G, Iv M, Choupan J, Hayden-Gephart M; Alzheimer’s Disease Neuroimaging Initiative. Barisano G, et al. EBioMedicine. 2024 Dec 24;111:105523. doi: 10.1016/j.ebiom.2024.105523. Online ahead of print. EBioMedicine. 2024. PMID: 39721217 Free article.
Longitudinal cognitive performance of participants with sporadic early onset Alzheimer's disease from LEADS.
Hammers DB, Eloyan A, Taurone A, Thangarajah M, Gao S, Beckett L, Polsinelli AJ, Kirby K, Dage JL, Nudelman K, Aisen P, Reman R, La Joie R, Lagarde J, Atri A, Clark D, Day GS, Duara R, Graff-Radford NR, Grant I, Honig LS, Johnson ECB, Jones DT, Masdeu JC, Mendez MF, Womack K, Musiek E, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Rabinovici GD, Dickerson BC, Apostolova LG; LEADS Consortium. Hammers DB, et al. Among authors: turner rs. Alzheimers Dement. 2024 Dec 23. doi: 10.1002/alz.14439. Online ahead of print. Alzheimers Dement. 2024. PMID: 39713873
Differences in baseline cognitive performance between participants with early-onset and late-onset Alzheimer's disease: Comparison of LEADS and ADNI.
Hammers DB, Eloyan A, Thangarajah M, Taurone A, Beckett L, Gao S, Polsinelli AJ, Kirby K, Dage JL, Nudelman K, Aisen P, Reman R, La Joie R, Lagarde J, Atri A, Clark D, Day GS, Duara R, Graff-Radford NR, Honig LS, Jones DT, Masdeu JC, Mendez MF, Womack K, Musiek E, Onyike CU, Riddle M, Grant I, Rogalski E, Johnson ECB, Salloway S, Sha SJ, Turner RS, Wingo TS, Wolk DA, Carrillo MC, Dickerson BC, Rabinovici GD, Apostolova LG; LEADS Consortium 1 for the Alzheimer's Disease Neuroimaging Initiative. Hammers DB, et al. Among authors: turner rs. Alzheimers Dement. 2024 Dec 23. doi: 10.1002/alz.14218. Online ahead of print. Alzheimers Dement. 2024. PMID: 39711228
4,925 results